September 2016
Together we can Cure Duchenne!
Research
oct2015_thumb04

CureDuchenne Celebrates FDA Approval of First Drug for Duchenne Muscular Dystrophy

CureDuchenne applauds the first-ever approval of a drug in the U.S. to treat Duchenne muscular dystrophy. The drug, Exondys 51 (eteplirsen), manufactured by Sarepta Therapeutics, Inc., received accelerated approval on September 19 from the Food and Drug Administration (FDA)...

Read more.

oct2015_thumb04

Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, announced on September 7 that the randomized Phase I/II HOPE-Duchenne clinical trial has completed its enrollment with 25 subjects...

Read more.

oct2015_thumb04

Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND Application

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced on August 25 that the U.S. Food and Drug Administration (FDA) has granted the company's request for a Fast Track designation for its Investigational New Drug (IND) application for Synacthen® Depot in the treatment of Duchenne muscular dystrophy (DMD)...

Read more.

oct2015_thumb04

Marathon Pharmaceuticals Announces Neurology Publication of Pivotal Phase 3 Data for Deflazacort for Duchenne Muscular Dystrophy

Marathon Pharmaceuticals LLC announced the publication of pivotal Phase 3 data evaluating the investigational drug deflazacort for the treatment of Duchenne muscular dystrophy in the journal Neurology. Data are currently available online and will appear in the print edition this fall...

Read more.

oct2015_thumb04

Santhera’s Idebenone(Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia

Santhera Pharmaceuticals (SWX:SANN), announced September 8 that the Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation (ODD) to idebenone (Raxone) for the treatment of Duchenne muscular dystrophy (DMD)...

Read more.

oct2015_thumb04

FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)

Phrixus Pharmaceuticals is announcing that FDA allowed Phrixus’s IND for Carmeseal-MD (P-188 NF) in Duchenne muscular dystrophy (DMD). The protocol that forms the basis of this IND includes a two-arm, randomized, double-blinded design with 120 patients in several centers in which one dose of P-188 NF will be evaluated against standard of care over 48 weeks...

Read more.

oct2015_thumb04

Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, announced September 28 the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping...

Read more.

oct2015_thumb04

Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids

Santhera Pharmaceuticals (SIX: SANN) announces that the first patient has been enrolled at the University of Kansas Medical Center (KUMC), Department of Neurology, Kansas (USA) in Santhera’s randomized, double-blind, placebo-controlled phase III (SIDEROS) trial...

Read more.

oct2015_thumb04

Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company (“Catabasis”), and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics (“Sarepta”), today announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD)...

Read more.

CureDuchenne Cares
sept2016_thumb17

CureDuchenne Cares Hosts Inaugural Family Summit This October

The inaugural CureDuchenne Cares Family Summit, a complimentary educational seminar for families who have loved ones with Duchenne muscular dystrophy, will take place on Saturday, October 22 at the Hyatt Regency in Garden Grove, CA...

Read more.

sept2016_thumb17

Charlotte CureDuchenne Cares Session Provides Resources and Connections for Families

On Saturday, September 24, 2016, CureDuchenne Cares held another successful Family Workshop in Charlotte, North Carolina. This event drew in families from North Carolina, South Carolina and Georgia...

Read more.

sept2016_thumb17

Spotlight on Dani Trees, PT, CureDuchenne Cares Certified Physical Therapist

Every Duchenne parent wants to know that their child is in good hands with their medical team. Physical therapy is an important part of that medical team, and Texas physical therapist Dani Trees wants to reassure parents she has the best training necessary to properly care for their child...

Read more.

News
Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2016 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the Duchenne muscular dystrophy (DMD) community...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Dealing for Duchenne Charity Casino Night Brings Together Cambridge Business Leaders to Benefit Lives of Those Living with Duchenne Muscular Dystrophy

CureDuchenne and Art In Giving announced they are co-hosting Dealing for Duchenne in Cambridge on October 20 in the heart of Kendall Square to help save the lives of those with Duchenne muscular dystrophy...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

San Antonio, Children with Duchenne Muscular Dystrophy Need Your Help

CureDuchenne, a national non-profit, and local families have joined to raise funds for research and new treatments for children afflicted with Duchenne muscular dystrophy, the most devastating and fatal muscular disease in children...

Read more.

Recent Success
Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

First Duchenne Drug Approved by the FDA

The FDA grants accelerated approval to the first drug for Duchenne muscular dystrophy. CureDuchenne provided early funding to Sarepta Therapeutics for the development of this drug. This provides hope to all Duchenne families and this is a huge step forward in turning Duchenne from a fatal disease to a more manageable condition...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Clay Matthews Supports CureDuchenne

Clay Matthews from the Green Bay Packers is proud to support CureDuchenne in their mission to find a cure for Duchenne muscular dystrophy. The FDA granted accelerated approval to Sarepta for the first drug for Duchenne muscular dystrophy...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Anaheim Ducks Captain Ryan Getzlaf Raises $380,000 to Find a Cure for Duchenne Muscular Dystrophy at the 6th Annual Getzlaf Golf Shootout

For the sixth year, the captain of the Anaheim Ducks Ryan Getzlaf and a team of professional athletes supported the 6th annual Getzlaf Golf Shootout, presented by ActivePDF, on August 26 and 27 to help CureDuchenne find a cure for Duchenne muscular dystrophy...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

CureDuchenne Receives Global Duchenne Muscular Dystrophy Patient Group Award

CureDuchenne is pleased to announce that on this World Duchenne Awareness Day, the organization has received one of the sought-after STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), created by PTC Therapeutics, Inc. to aid nonprofit organizations committed to serving the Duchenne muscular dystrophy community...

Read more.

Upcoming Events
CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

All in for Duchenne, October 15, Sylvania, OH

The annual All in for Duchenne event benefiting CureDuchenne is on October 15 from 6 p.m. to 11 pm...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

Dealing for Duchenne, October 15, San Antonio, TX

Join us for a night of hope at the Dealing for Duchenne San Antonio on October 15...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

Dealing for Duchenne, October 20, Cambridge, MA

A Vegas gaming night to benefit the cure for Duchenne will be held on October 20 from 6 p.m. to 10 p.m. at 650 East Kendall Street in Cambridge, MA...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

CureDuchenne Cares Family Summit, October 22, Garden Grove, CA

Join us for the CureDuchenne Cares Family Summit on October 22. It is a free educational event for families who have loved ones with Duchenne muscular dystrophy...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

Napa In Newport, March 4, 2017, Laguna, Nigel, CA

Reserve the date for Napa In Newport on March 4, 2017 at the Ritz-Carlton, Laguna Niguel...

Read more.

Powered By Convio